IRLAB and research consortium awarded MSEK 2.9 Vinnova grant

IRLAB announced today that a research consortium, where IRLAB is one part has received a 2.9 MSEK grant from The Swedish Governmental Agency for Innovation Systems (Vinnova’s) program “Swelife and Medtech4Health – Collaboration project for better health spring 2019.” The research consortium comprises academic research groups at Karolinska Institute, Lund / Umeå University and IRLAB. The funded research project aims to deepen the understanding of Parkinson’s disease (PD), its specific symptoms, with the objective to advance much needed treatments.

The project will be coordinated by Dr. Per Petersson, Associate Professor in integrative neurophysiology at Lund and Umeå University. Dr. Per Svenningsson, Professor and senior physician at Karolinska Institutet and IRLAB participates in the consortium. Building upon Petersson’s, Svenningsson’s and IRLAB’s expertise, the project aims to deepen the knowledge about symptoms of Parkinson’s disease, as well as potential future treatments.

Petersson’s research group at Lund and Umeå University and Professor Per Svenningsson have developed methods that make it possible to determine how disease-specific activity patterns in different parts of the brain is associated to symptoms of PD and how long term treatment with levodopa, the standard of care in PD, alter brain functions and how these alterations can be treated. IRLAB is developing novel treatment strategies in PD.

Nicholas Waters, CEO at IRLAB, commented “We are pleased to see that investments at the national level is made into research about Parkinson’s disease, its causes and treatment, where there is a great need for deeper understanding and novel therapies. It is an honor for us to work together with such reputed academic partners as Per Petersson and Per Svenningsson and their teams, we look forward to this collaboration.”

The program “Swelife and Medtech4Health – Collaboration project for better health spring 2019” is a joint project by Vinnova, Formas and the Swedish Energy Agency with the aim of financing innovative projects with a great potential to contribute to improved prevention, diagnosis, monitoring or treatment in areas where there is a significant need and demand for the solution from the end user.

For further information

Nicholas Waters, CEO                
Phone: +46 730 75 77 01                
E-mail: nicholas.waters@irlab.se

About Swelife
Swelife – For a competitive life science ecosystem in Sweden

Swelife is a strategic innovation programme, funded by the Swedish Government via the Swedish innovation agency, Vinnova, and by the programme’s partners. We support collaboration within academia, industry and healthcare, with the goal to strengthen Life Science in Sweden and to improve public health.

About IRLAB

IRLAB is a Swedish biotech company focused on Parkinson's disease. The company's clinical Phase 2 candidates, IRL752 and IRL790, intend to treat some of the most difficult symptoms related to Parkinson's disease: involuntary movements (LIDs), psychosis and dementia. Through the proprietary ISP (Integrative Screening Process) research platform, IRLAB discovers and develops drug candidates for central nervous system (CNS) related diseases where big growing medical needs exist. In addition to the clinical candidates, the ISP platform has also generated several CNS programs that are now in preclinical phase. IRLAB's Certified Adviser on Nasdaq First North is FNCA Sweden AB, info@fnca.se, +46 (0)8‑528 00 399. More information on www.irlab.se.

Subscribe

Documents & Links

Quotes

We are pleased to see that investments at the national level is made into research about Parkinson’s disease, its causes and treatment, where there is a great need for deeper understanding and novel therapies. It is an honor for us to work together with such reputed academic partners as Per Petersson and Per Svenningsson and their teams, we look forward to this collaboration.
Nicholas Waters, CEO